Risk Factors for Pneumocystis jirovecii Pneumonia in Patients With Rheumatoid Arthritis and a Prophylactic Indication of Trimethoprim/Sulfamethoxazole Kazutoshi Yukawa, Yasutsugu Nagamoto , Hirofumi Watanabe, Masamoto Funaki, Mitsuhiro Iwahashi, Jiro Yamana, Rie Sasaki, Seizo Yamana J Clin Rheumatol . 2018 Oct;24(7):355-360.
Serum CXCL10 levels are associated with better responses to abatacept treatment of rheumatoid arthritis. Yukawa K, Yamana J, Iwahashi M, Yamana S, Sugiyama E. et.al. Clin Exp Rheumatol. 2020 Sep-Oct;38(5):956-963. Epub 2020 Jan 20.
トシリズマブによるTOWARD study
山名 二郎 リウマチ科 43(1):80-87, 2010
【関節リウマチ(第2版) 寛解を目指す治療の新時代】 関節リウマチの合併症 二次性アミロイドーシス
岩橋 充啓 日本臨床(0047-1852)68巻増刊号5 関節リウマチ Page531-535,2010
【プライマリ・ケア医のための関節リウマチ診療のすべて】 【適切に治療するために】
疾患活動性の評価方法と治療目標の設定
岩橋 充啓JIM: Journal of Integrated Medicine20巻10号 760-763(2010.10)
生物学的製剤におけるトシリズマブの位置づけ
岩橋 充啓 リウマチ科45巻6号 Page653-658(2011.06)
【リウマチ生物学的製剤の効果的な使い方】 低分子抗リウマチ薬併用の有用性
岩橋 充啓:Orthopaedics, 2011
関節リウマチ薬物治療 これだけは知っておきたいブシラミンが処方される理由(第2回) ブシラミンを適切に使うには
岩橋 充啓 レジデントノート13巻13号 Page2457-2461(2012.01)
Safety and Efficacy of Various Dosages of Ocrelizumab in Japanese Patients with Rheumatoid Arthritis with an Inadequate Response to Methotrexate Therapy: A Placebo-controlled Double-blind Parallel-group Study.
Harigai M, et.al. Yamana S, Iwahashi M, J Rheumatol. 2012 Mar;39(3):486-495. Epub 2012 Jan 15.
【栄養ケアマネジメントファーストトレーニング 循環器・腎疾患】 膠原病の栄養ケアマネジメント
藤竹 樹美、臨床栄養別冊NCMシリーズ2 循環器・腎疾患 Page120-127 2012
Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.
Watanabe K,et.al. Iwahashi M, Mod Rheumatol. 2012 Dec 5.
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
van der Heijde D, et.al. Iwahashi M, Arthritis Rheum. 2013 Mar;65(3):559-70. doi: 10.1002/art.37816.
Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.
Nishimoto N, et.al. Iwahashi M, Yamana J, Mod Rheumatol. 2013 May 17. [Epub ahead of print]
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
Nishimoto N, et.al. Iwahashi M, Yamana J, Mod Rheumatol. 2013 May 3. [Epub ahead of print]
Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Song SN, et al. Iwahashi M, Yamana J, Yamana S Arthritis Res Ther. 2013 Oct 2;15(5):R141.
Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Ogata A, et al. Iwahashi M; Musashi Study Investigators. Arthritis Care Res (Hoboken). 2014 Mar;66(3):344-54.
Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. Iwahashi M, et al. Mod Rheumatol. 2014 Nov;24(6):885-91.
Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. Amano K, et al. Iwahashi M; Japan Abatacept Study Group. Mod Rheumatol. 2015 Sep;25(5):665-71.
Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population. Terao C, et al. Iwahashi M Arthritis Res Ther. 2015 Apr 18;17:104.
Pretreatment Prediction of Individual Rheumatoid Arthritis Patients’ Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers. Uno K, Yoshizaki K, et al. Iwahashi M, Yamana J, Yamana S PLoS One. 2015 Jul 15;10(7):e0132055.